Day One Biopharmaceuticals Reports Strong OJEMDA Revenue Growth and Reaffirms Robust 2026 Guidance
Summary
Day One Biopharmaceuticals announced strong fourth quarter and full-year 2025 financial results, driven by significant OJEMDA revenue growth, and reaffirmed its positive 2026 revenue guidance.
Key Events
-
Strong OJEMDA Revenue Growth
Reported $155.4 million in OJEMDA net product revenue for full-year 2025, a 172% increase year-over-year, with Q4 2025 revenue at $52.8 million.
-
Reaffirmed 2026 Revenue Guidance
Reaffirmed 2026 U.S. OJEMDA net product revenue guidance of $225 million to $250 million, projecting over 50% growth from 2025.
-
Solid Cash Position
Ended 2025 with $441.1 million in cash, cash equivalents, and short-term investments, providing a strong financial runway.
-
Pipeline Progress
Announced FIREFLY-2 trial enrollment completion expected in 1H 2026, and anticipated Phase 1 clinical data for Emi-Le (mid-2026) and DAY301 (2H 2026).
Analysis
The company reported a substantial 172% year-over-year increase in OJEMDA net product revenue for 2025, reaching $155.4 million. This strong commercial performance is expected to continue, with 2026 U.S. OJEMDA net product revenue projected at $225 million to $250 million, representing over 50% growth from 2025. While the net loss increased, the company maintains a solid cash position of $441.1 million. Key pipeline programs, including the pivotal FIREFLY-2 trial and the recently acquired Emi-Le, are progressing, with important data updates anticipated in 2026. This report signals continued commercial momentum and pipeline advancement, which are critical for a growth-stage biopharmaceutical company.
At the time of this filing, DAWN was trading at $12.02 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $5.64 to $13.20. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.